Neuropharmacology, Journal Year: 2022, Volume and Issue: 223, P. 109299 - 109299
Published: Nov. 3, 2022
Language: Английский
The Lancet Psychiatry, Journal Year: 2022, Volume and Issue: 9(11), P. 907 - 921
Published: Oct. 14, 2022
Language: Английский
Citations
97
European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2024, Volume and Issue: unknown
Published: Feb. 27, 2024
The growing interest in the rapid and sustained antidepressant effects of dissociative anesthetic ketamine classic psychedelics, such as psilocybin, is remarkable. However, both psychedelics are known to induce acute mystical experiences; can cause symptoms out-of-body experience, while typically bring about hallucinogenic experiences, like a profound sense unity with universe or nature. role these experiences enhancing outcomes for patients depression currently an area ongoing investigation debate. Clinical studies have shown that following administration (S)-ketamine (esketamine) not directly linked their properties. In contrast, potential (R)-ketamine (arketamine), thought lack side effects, has yet be conclusively proven large-scale clinical trials. Moreover, although activation serotonin 5-HT
Language: Английский
Citations
29
Neuropharmacology, Journal Year: 2022, Volume and Issue: 222, P. 109305 - 109305
Published: Oct. 30, 2022
Language: Английский
Citations
60
Journal of Affective Disorders, Journal Year: 2023, Volume and Issue: 339, P. 815 - 822
Published: July 22, 2023
Postpartum depression (PPD) is a prevalent public health issue. Although ketamine has prophylactic effects on PPD in women undergoing cesarean section, the of esketamine remain unclear. This trial aimed to evaluate efficacy perioperative infusion risk by assessing Edinburgh Postnatal Depression Scale (EPDS) scores and blood biomarkers.A total 150 participants elective section were randomly allocated receive either or normal saline. Since 27 excluded due consent withdrawal loss follow-up, 123 patients included. The primary outcome was prevalence risk. Secondary outcomes included postpartum anxiety (PPA) risk, levels biomarkers, postoperative pain intensity, cumulative sufentanil consumption.The PPA at 3 days, 42 months, 6 months did not differ between two groups. Furthermore, EPDS scores, intensity rest, during coughing days (POD) 1 2 Sufentanil consumption 0-12 h, 12-24 0-24 0-48 h postoperatively significantly lower group compared control group. Blood biomarkers groups POD 3.The sample size small. simply screened, diagnosed.Perioperative administration decrease incidence after section. However, reduced opioid consumption.
Language: Английский
Citations
41
European Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 70, P. 49 - 55
Published: March 1, 2023
Language: Английский
Citations
38
Drug Discovery Today, Journal Year: 2023, Volume and Issue: 28(4), P. 103518 - 103518
Published: Feb. 8, 2023
Language: Английский
Citations
36
Neuropharmacology, Journal Year: 2023, Volume and Issue: 226, P. 109422 - 109422
Published: Jan. 13, 2023
Language: Английский
Citations
33
European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2023, Volume and Issue: 273(7), P. 1513 - 1525
Published: Feb. 14, 2023
Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) these patients, have not found to cognitive impairment. The N-methyl-D-aspartate receptor antagonist (R,S)-ketamine attracted attention as a rapidly acting antidepressant. In addition its robust antidepressant effects, suggested MDD BD, despite causing healthy control subjects. is racemic mixture of equal amounts (R)-ketamine (or arketamine) (S)-ketamine esketamine). Arketamine more potent antidepressant-like actions than esketamine rodents. Interestingly, arketamine, but esketamine, phencyclidine-induced deficits mice. Furthermore, arketamine ameliorate rodent offspring after maternal immune activation. the current article, it proposed that potential for treating disorders. Additionally, role gut-microbiome-brain axis disorders discussed.
Language: Английский
Citations
32
Progress in brain research, Journal Year: 2023, Volume and Issue: unknown, P. 61 - 77
Published: Jan. 1, 2023
Language: Английский
Citations
31
Molecular Psychiatry, Journal Year: 2023, Volume and Issue: unknown
Published: Jan. 20, 2023
Abstract Ketamine, a commonly used general anesthetic, can produce rapid and sustained antidepressant effect. However, the efficacy safety of perioperative application ketamine on postoperative depression remains uncertain. We performed meta-analysis to determine effect intravenous administration depression. Randomized controlled trials comparing with placebo in patients were included. Primary outcome was scores. Secondary outcomes included visual analog scale (VAS) scores for pain adverse effects associated ketamine. Fifteen studies 1697 receiving 1462 controls enrolled. Compared controls, group showed reduction scores, by standardized mean difference (SMD) −0.97, 95% confidence interval [CI, −1.27, −0.66], P < 0.001, I 2 = 72% day (POD) 1; SMD−0.65, CI [−1.12, −0.17], 94% POD 3; SMD−0.30, [−0.45, −0.14], 0% OD 7; SMD−0.25, [−0.38, −0.11], 59% over long term. Ketamine reduced VAS 1 (SMD−0.93, [−1.58, −0.29], 0.005, 97%), but no significant found between two groups PODs 3 7 or distinctly increased risk effects, including nausea vomiting (risk ratio [RR] 1.40, [1.12, 1.75], 0.003, 30%), headache (RR 2.47, [1.41, 4.32], 0.002, 19%), hallucination 15.35, [6. 4, 37.34], 89%), dizziness 3.48, [2.68, 4.50], 89%) compared controls. In conclusion, reduces effects.
Language: Английский
Citations
27